<DOC>
	<DOCNO>NCT00430768</DOCNO>
	<brief_summary>Individuals deficiency alpha 1-antitrypsin ( AAT ) protein risk develop emphysema liver damage . Researchers develop way introduce normal AAT gene muscle cell expectation AAT protein may produce normal level . This study evaluate safety experimental gene transfer procedure individual AAT deficiency . The study also determine dose may require achieve normal level AAT .</brief_summary>
	<brief_title>Experimental Gene Transfer Procedure Treat Alpha 1-Antitrypsin ( AAT ) Deficiency</brief_title>
	<detailed_description>AAT deficiency genetic disorder individual inadequate level AAT protein . AAT protect lung white blood cell enzymes damage air sac within lung , potentially leading emphysema . Experimental gene transfer procedure , normal copy gene insert cell , develop treat many genetic disease , include AAT deficiency . In study , modify virus , adeno-associated virus ( AAV ) , genetically engineer contain normal copy AAT gene . When AAV combine AAT gene , result agent , Recombinant Adeno-Associated Virus Alpha 1-Antitrypsin ( rAAV1-CB-hAAT ) Gene Vector chicken beta actin promoter ( CB ) , may able carry normal copy AAT gene muscle cell expectation additional AAT would produce . The purpose study evaluate safety inject rAAV1-CB-hAAT individual AAT deficiency . This 14-month study enroll individual AAT deficiency . Participants currently use AAT protein replacement discontinue use 19 week study . Participants first attend baseline study visit , include medical history review ; physical examination ; electrocardiogram ( ECG ) record heart activity ; blood , urine , semen collection ; pulmonary function test ; chest arm scan . Participants attend 5-day inpatient visit , receive series injection consist one four different dos rAAV1-CB-hAAT . Physical examination occur 5 inpatient day ; pulmonary function testing , arm circumference measurement , collection blood , urine , semen occur select day inpatient stay . Follow-up study visit , possible overnight stay , occur Days 14 90 . On Days 30 , 45 , 60 , 75 , 180 , 270 , 365 , participant blood draw local clinic . On day , study staff contact participant telephone review medical history symptom . Unused blood semen sample frozen store future research purpose . Participants yearly follow-up evaluation either telephone mail total 5 year .</detailed_description>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<criteria>Diagnosed AAT deficiency Forced expiratory volume one second ( FEV1 ) great 24 % predict value ( post bronchodilator ) Willing discontinue AAT protein replacement 4 week ( Group 1 ) 8 week ( Groups 2 3 ) prior study entry , resume 11 week rAAV1CBhAAT administer Willing discontinue aspirin , aspirincontaining product , drug may alter platelet function 7 day prior study entry , resume 24 hour rAAV1CBhAAT administer Willing use contraception throughout study Required antibiotic therapy respiratory infection 28 day prior rAAV1CBhAAT administration Required oral systemic corticosteroid 28 day prior rAAV1CBhAAT administration Liver disease Currently receive receive investigational study agent 30 day prior study entry Received gene transfer agent 6 month prior study entry Currently smoke cigarette use illegal drug History immune response human AAT replacement History platelet dysfunction Abnormal ECG , heart disease , pulmonary edema , embolism 6 month prior study entry Current recent facial chest trauma make medically impossible perform pulmonary function test ( PFTs ) Any medical condition investigator deem unsuitable study participation Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Gene Transfer Techniques</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>AAV</keyword>
	<keyword>AAT</keyword>
	<keyword>Phase I</keyword>
	<keyword>Intramuscular transfer</keyword>
</DOC>